Reports of large granular lymphocytic (LGL) leukemia after hematopoietic stem cell transplant (HSCT) have appeared in the literature for two decades. However, much information has been obtained by several recent studies. [1] [2] [3] [4] These studies have reported a large percentage of asymptomatic patients as well as improved rates of survival and primary disease relapse, leading some to conclude that HSCT-associated LGL leukemia should be viewed as a potentially beneficial, reactive response to HSCT rather than a true neoplastic condition. [2] [3] [4] Nevertheless, comparison of these studies is limited by unavoidable heterogeneity in terminology, diagnostic criteria and patient populations, including inclusion of patients with both clonal and oligoclonal LGL expansion.
In addition, LGL leukemia has been shown to have increased activity of the STAT3 signaling pathway with~30-40% of cases harboring single or multiple somatic mutations of the STAT3 gene. [5] [6] [7] [8] However, studies evaluating this pathway in HSCT-associated cases are lacking. The mutation involves the Src homology 2 domain of the gene, which is responsible for dimerization and activation/phosphorylation of the STAT3 protein. STAT3 mutation has been demonstrated in both T-cell and natural killer (NK) cell-derived cases, and is associated with increased phosphorylated STAT3 protein (pSTAT3) which can be visualized by immunohistochemistry (IHC). 6, 7 Furthermore, increased pSTAT3 and STAT3 activity has been demonstrated in both STAT3-mutated and wild-type LGL leukemia when strict diagnostic criteria are used. 7 In order to better understand this rare disease, we used strict diagnostic criteria to identify seven patients who developed LGL leukemia following HSCT and used IHC to assess for nuclear localization of pSTAT3 in leukemic cells.
Clinical and laboratory data were obtained from the electronic medical record, and the study was conducted in accordance with an institutional internal review board-approved protocol. We searched our hospital database from 1 January 2004 to 31 December 2014 for patients who met criteria for LGL leukemia based on recent guidelines. [9] [10] [11] Patients who had undergone either allogeneic or autologous HSCT and who met the following criteria were included: increased (⩾0.5 × 10 9 /L) LGLs of either cytotoxic T-cell (CTC) or NK cell lineage in the peripheral blood for ⩾ 6 months; presence of bone marrow (BM) involvement; and demonstration of clonal T-cell receptor (TCR) gene rearrangement by PCR or a monotypic pattern of CD158/KIR isoform expression by flow cytometry for cases of NK cell lineage.
Interval of disease development was calculated from date of HSCT to date of detection of increased LGLs in peripheral blood. Follow-up time and survival were calculated from date of HSCT to date of last follow-up or death. Patients with increased LGLs, BM involvement or cytopenias at date of death or last follow-up were classified as having persistent disease. Patients with increasing peripheral blood LGLs, increasing BM involvement, worsening cytopenias or development of additional malignancy at date of death or last follow-up were classified as having progressive disease.
Immunohistochemical studies to assess for nuclear expression of pSTAT3 were performed on BM core biopsy specimens from six of seven patients with available material using a mouse monoclonal Ab against a sequence containing human STAT3 phosphorylated at Tyr-705 (pSTAT3: sc-8059) (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Specimens underwent Ag retrieval in a pressure chamber before manual application of a 1:50 dilution of anti-pSTAT3 followed by 24-h incubation at 4°C. Epithelial cells from a tissue microarray were used as a positive control. A microarray of BM from patients without hematopoietic disease was used as a negative control. The presence of nuclear staining in the BM lymphoid infiltrate of equal or greater intensity to that seen in the positive control material was considered a positive result and percentage of positivity was manually estimated.
Out of 158 patients who met our criteria for LGL leukemia during the selected time frame, we identified seven (4.4%) who had undergone HSCT (Table 1) . Four patients received allogeneic HSCT and three received autologous HSCT. All four patients who underwent allogeneic HSCT received a reduced conditioning regimen before transplant. Microsatellite polymorphism analysis confirmed complete engraftment by donor stem cells in all four patients who received allogeneic HSCT, indicating that LGL leukemia was of donor origin. The median time to detection of LGL proliferation for the entire study group was 16 months (range, 5-36 months). Abbreviations: Allo = allogeneic transplant; AML-MRC = AML with myelodysplasia-related changes; Auto = autologous transplant; BM = percentage of bone marrow involvement; CTCL = cytotoxic T cell; DLBCL = diffuse large B-cell lymphoma; F = female; Interval = detection of LGL leukemia from time of transplant;
LGL = large granular lymphocytic; M = male; Neg = negative; NK = natural killer; NP = testing not performed; pSTAT3 = expression of phosphorylated STAT3 by immunohistochemistry; Pos = positive; Pt = patient number; αβ = alpha beta; γδ = gamma delta.
All patients showed BM involvement ranging from 20 to 50% of BM cellularity (Table 1) . By flow cytometry, patient 1 (Table 1) showed an NK cell immunophenotype with a monoclonal pattern of CD158 expression. Patients 2-7 showed a CTC immunophenotype and four of these patients showed aberrant expression of CD2, CD3, CD5, CD7 and/or CD8. PCR showed monoclonal rearrangement of the TCR γ and/or β gene in patients 2-7, and germline arrangement of the TCR γ and β genes in patient 1.
All patients remained in CR from their original neoplasm. However, in contrast to previous reports, all of our patients were symptomatic. All seven patients had persistent or progressively increased LGLs in the peripheral blood. Anemia and thrombocytopenia were frequent findings and resulted in chronic transfusion dependence in three patients (patients 1, 3 and 5; Table 2 ). Neutropenia was present in 4/7 patients and 5/7 had infectious disease ( Table 2) . Two patients (patients 5 and 7; Table 2 ) had splenomegaly.
Several patients required treatment, but showed minimal response to several lines of therapy ( Table 2 ). At the end of the study period (median follow-up, 11 months; range, 6-96 months), four patients were alive: one with persistent disease and three with progressive disease, including one patient who developed a secondary, non-hematologic neoplasm (patient 2, Table 2 ). Three patients expired due to complications of disease: one with persistent disease and two with progressive disease.
Immunohistochemical stain for pSTAT3 showed positive nuclear staining in a subset of LGL cells, ranging from 10 to 20% of the infiltrate, in five of six patients (83%) with material available for testing (Supplementary Figure 1) . Two patients (patients 4 and 7, Table 1 ) had a second, subsequent sample (taken at 6 and 24 months, respectively) available for testing. Both samples were also positive for pSTAT3. Patient 2 showed scattered nuclear positivity (~1% of cells) for pSTAT3, but the positive cells could not be definitively localized to the lymphoid infiltrate and the sample was classified as negative.
Thus, using strict diagnostic criteria and ancillary studies such as PCR and flow cytometry, we found that a subset of patients who undergo HSCT may develop LGL leukemia with potential for significant symptomatology and mortality. Although some of the observed complications such as LGL proliferation, cytopenias and infectious disease can be seen in the post-HSCT setting, these findings were detected several months after HSCT and were either persistent or progressive.
Furthermore, we found that a significant subset of such patients (83%) show nuclear expression of phosphorylated pSTAT3 protein by IHC, which has been associated with activation of the STAT3 pathway and STAT3 mutation. 6, 7 The retrospective nature of our study precluded us from analyzing our patient population for STAT3 mutation. However, evidence of increased STAT3 activity has been shown in patients meeting strict criteria for LGL leukemia with both wild-type and mutated STAT3.
6-8 Jerez et al.
7
showed that both cases of STAT3-mutated and wild-type LGL leukemia produce increased amounts of pSTAT3 and both types showed similar profiles of dysregulation in genes involved in apoptosis. Thus, other mechanisms of increased STAT3 activity in LGL leukemia may exist but likely confer similar features. Therefore, we believe our findings justify further study of this pathway in cases of HSCT-associated LGL leukemia for both diagnostic and therapeutic purposes. There is evidence that STAT3 activation can help identify patients with LGL leukemia versus reactive LGL expansion. Jerez et al. 7 used criteria similar to those we applied to identify 170 patients with LGL leukemia and 31 with neutropenia and circulating LGLs who did not meet their diagnostic criteria. STAT3 mutations were found only in the former group. Furthermore, the presence of STAT3 mutation has been associated with higher rates of symptomology and increased need for therapy. [6] [7] [8] Rajala et al. 8 showed that up to 17% of patients with LGL leukemia may have multiple STAT3 mutations present in different lymphocyte clones and that failure of conventional treatment agents such as methotrexate and cyclophosphamide to eliminate these clones was associated with treatment failure. Such findings may help explain why some cases of HSCT-associated LGL leukemia, such as those in our study, show higher rates of symptomatology and treatment resistance. They also strengthen the argument that such cases share a similar pathogenesis to non-transplant-associated cases and should be viewed as true neoplastic disease. Finally, as previous reports have shown increased apoptosis in leukemic LGL cells treated with agents Letter to the Editor targeting the STAT3 pathway, our findings suggest a need for similar studies in HSCT-associated cases. 5, 7 In summary, our findings support the notion that a subset of patients develop true LGL leukemia after HSCT and that such cases may involve activation of the STAT3 pathway. We hope that our findings will encourage more detailed study of this pathway in post-transplant patients.
